ANI Pharmaceuticals Inc (ANIP)
65.57
+0.09
(+0.14%)
USD |
NASDAQ |
Apr 22, 16:00
65.56
-0.01
(-0.02%)
After-Hours: 20:00
ANI Pharmaceuticals Cash from Financing (TTM): 67.44M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 67.44M |
September 30, 2023 | 78.85M |
June 30, 2023 | 74.18M |
March 31, 2023 | -7.404M |
December 31, 2022 | -5.126M |
September 30, 2022 | 174.83M |
June 30, 2022 | 172.72M |
March 31, 2022 | 195.05M |
December 31, 2021 | 194.60M |
September 30, 2021 | 12.94M |
June 30, 2021 | 13.59M |
March 31, 2021 | -18.06M |
December 31, 2020 | -1.439M |
September 30, 2020 | 0.003M |
June 30, 2020 | 1.611M |
March 31, 2020 | 13.94M |
December 31, 2019 | 1.25M |
September 30, 2019 | -25.93M |
June 30, 2019 | -25.89M |
March 31, 2019 | -26.78M |
December 31, 2018 | -27.82M |
September 30, 2018 | 47.56M |
June 30, 2018 | 43.35M |
March 31, 2018 | 42.50M |
December 31, 2017 | 72.36M |
Date | Value |
---|---|
September 30, 2017 | 25.45M |
June 30, 2017 | 31.54M |
March 31, 2017 | 31.65M |
December 31, 2016 | -0.729M |
September 30, 2016 | -1.073M |
June 30, 2016 | -1.505M |
March 31, 2016 | -1.307M |
December 31, 2015 | 1.066M |
September 30, 2015 | 124.48M |
June 30, 2015 | 124.22M |
March 31, 2015 | 123.95M |
December 31, 2014 | 171.65M |
September 30, 2014 | 48.88M |
June 30, 2014 | 48.42M |
March 31, 2014 | 44.04M |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 67.66M |
September 30, 2011 | 85.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-25.93M
Minimum
Sep 2019
195.05M
Maximum
Mar 2022
48.27M
Average
12.94M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Ligand Pharmaceuticals Inc | -59.95M |
ADMA Biologics Inc | -38.99M |
Dentsply Sirona Inc | -307.00M |
Allogene Therapeutics Inc | 95.70M |
Vanda Pharmaceuticals Inc | -- |